A Personalized Approach to Pancreatic Ductal Adenocarcinoma and its Application in Surgical Practice

References

• Tarver T . Cancer Facts & Figures 2012. American Cancer Society (ACS). J. Consum. Health Internet16(3), 366–367 (2012).
   Google Scholar
• Rahib L , SmithBD , AizenbergR , RosenzweigAB , FleshmanJM , MatrisianLM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res.74(11), 2913–2921 (2014).
   PubMed Web of Science ®Google Scholar
• Imamura M , DoiR , ImaizumiTet al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery136(5), 1003–1011 (2004).
   PubMed Web of Science ®Google Scholar
• Bilici A . Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J. Gastroenterol.20(31), 10802 (2014).
   PubMed Web of Science ®Google Scholar
• Bateni SB , GingrichAA , HochJS , CanterRJ , BoldRJ. Defining value for pancreatic surgery in early-stage pancreatic cancer. JAMA Surgery154(10), e193019 (2019).
   PubMed Web of Science ®Google Scholar
• Zeng S , PöttlerM , LanB , GrützmannR , PilarskyC , YangH. Chemoresistance in pancreatic cancer. Int. J. Mol. Sci.20(18), 4504 (2019).
   PubMed Web of Science ®Google Scholar
• Sivakumar S , DeSantiago I , ChlonL , MarkowetzF. Master regulators of oncogenic KRAS response in pancreatic cancer: an integrative network biology analysis. PLoS Med.14(1), e1002223 (2017).
   PubMed Web of Science ®Google Scholar
• Griffin JF , PorukKE , WolfgangCL. Pancreatic cancer surgery: past, present, and future. Chin. J. Cancer Res.27(4), 332–348 (2015).
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines . Pancreatic Adenocarcinoma (Version 3.2019) (2019). http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
   Google Scholar
• Xue Y , WilcoxWR. Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. Cancer Biol. Med.13(1), 12–18 (2016).
   PubMed Web of Science ®Google Scholar
• Tsai HJ , ChangJS. Environmental risk factors of pancreatic cancer. J. Clin. Med.8(9), 1427 (2019).
   PubMed Web of Science ®Google Scholar
• Zanini S , RenziS , LimongiAR , BellaviteP , GiovinazzoF , BermanoG. A review of lifestyle and environment risk factors for pancreatic cancer. Eur. J. Cancer145, 53–70 (2021).
   PubMed Web of Science ®Google Scholar
• Ben QW , LiuJ , SunYW , WangLF , ZouDW , YuanYZ. Cigarette smoking and mortality in patients with pancreatic cancer: a systematic review and meta-analysis. Pancreas48(8), 985–995 (2019).
   PubMed Web of Science ®Google Scholar
• Candido S , AbramsSL , SteelmanLet al. Metformin influences drug sensitivity in pancreatic cancer cells. Adv. Biol. Regul.68, 13–30 (2018).
   PubMedGoogle Scholar
• Menini S , IacobiniC , DeLatouliere Let al. The advanced glycation end-product N(ϵ)-carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention. J. Pathol.245(2), 197–208 (2018).
   PubMed Web of Science ®Google Scholar
• Vallianou N , KounatidisD. Mycobiome and cancer: what is the evidence?Cancers (Basel)13(13), 3149 (2021).
   PubMed Web of Science ®Google Scholar
• Archibugi L , SignorettiM , CapursoG. The microbiome and pancreatic cancer: an evidence-based association?J. Clin. Gastroenterol.52(Suppl. 1), S82–S85 (2018). Proceedings of: The 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting. Rome, Italy 10–, 12 September 2017.
   PubMedGoogle Scholar
• Wei MY , ShiS , LiangCet al. The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol. Cancer18(1), 97 (2019).
   PubMed Web of Science ®Google Scholar
• Geller LT , Barzily-RokniM. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science357(6356), 1156–1160 (2017).
   PubMed Web of Science ®Google Scholar
• Perez-Chanona E , TrinchieriG. The role of microbiota in cancer therapy. Curr. Opin. Immunol.39, 75–81 (2016).
   PubMed Web of Science ®Google Scholar
• Iida N , DzutsevA , StewartCAet al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science342(6161), 967–970 (2013).
   PubMed Web of Science ®Google Scholar
• Ogino S , NowakJA , HamadaT , MilnerDAJr , NishiharaR. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu. Rev. Pathol.14, 83–103 (2019).
   PubMed Web of Science ®Google Scholar
• Hasan S , JacobR , ManneU , PaluriR. Advances in pancreatic cancer biomarkers. Oncol. Rev.13(1), 410 (2019).
   PubMed Web of Science ®Google Scholar
• Golan T , KanjiZS , EpelbaumRet al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br. J. Cancer111(6), 1132–1138 (2014).
   PubMed Web of Science ®Google Scholar
• Wei X , MeiC , LiX , XieY. The unique microbiome and immunity in pancreatic cancer. Pancreas50(2), 119–129 (2021).
   PubMed Web of Science ®Google Scholar
• Karamitopoulou E . Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br. J. Cancer121(1), 5–14 (2019).
   PubMed Web of Science ®Google Scholar
• Jansen RJ , TanXL , PetersenGM. Gene-by-environment interactions in pancreatic cancer: implications for prevention. Yale J. Biol. Med.88(2), 115–126 (2015).
   PubMedGoogle Scholar
• Van Kampen JG , Marijnissen-VanZanten MA , SimmerF , VanDer Graaf WT , LigtenbergMJ , NagtegaalID. Epigenetic targeting in pancreatic cancer. Cancer Treat. Rev.40(5), 656–664 (2014).
   PubMed Web of Science ®Google Scholar
• Gonzalez RS . WHO classification. PathologyOutlines.com (2019). www.pathologyoutlines.com/topic/pancreaswho.html
   Google Scholar
• Schlitter AM , SeglerA , SteigerKet al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): identification of prognostic subtypes. Sci. Rep.7(1), 41064 (2017).
   PubMedGoogle Scholar
• Torres C , GrippoPJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann. Med.50(4), 277–287 (2018).
   PubMed Web of Science ®Google Scholar
• Jones S , ZhangX , ParsonsDWet al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science321(5897), 1801–1806 (2008).
   PubMed Web of Science ®Google Scholar
• Collisson EA , SadanandamA , OlsonPet al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med.17(4), 500–503 (2011).
   PubMed Web of Science ®Google Scholar
• Bailey P , ChangDK , NonesKet al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature531(7592), 47–52 (2016).
   PubMed Web of Science ®Google Scholar
• Moffitt RA , MarayatiR , FlateELet al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet.47(10), 1168–1178 (2015).
   PubMed Web of Science ®Google Scholar
• Waddell N , PajicM , PatchA-Met al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature518(7540), 495–501 (2015).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network . Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell32(2), 185–203.e113 (2017).
   PubMed Web of Science ®Google Scholar
• Zhao L , ZhaoH , YanH. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer18(1), 603 (2018).
   PubMedGoogle Scholar
• Janky R , BindaMM , AllemeerschJet al. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer16, 632 (2016).
   PubMed Web of Science ®Google Scholar
• Kim S , KangM , LeeSet al. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. Biomed. Eng. Online13(Suppl. 2), S5 (2014).
   PubMedGoogle Scholar
• Bertucci F , BirnbaumDJ , FinettiPet al. Prognostic value of molecular subtypes in pancreatic cancer. Pancreas46(4), e29–e31 (2017).
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ , FinettiP , BirnbaumD , MamessierE , BertucciF. Validation and comparison of the molecular classifications of pancreatic carcinomas. Mol. Cancer16(1), 168 (2017).
   PubMedGoogle Scholar
• Dreyer SB , JamiesonNB , Upstill-GoddardRet al. Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br. J. Surg.105(2), e183–e191 (2018).
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ , BertucciF , FinettiP , BirnbaumD , MamessierE. Head and body/tail pancreatic carcinomas are not the same tumors. Cancers11(4), 497 (2019).
   PubMed Web of Science ®Google Scholar
• Sahni S , MoonEA , HowellVMet al. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. Eur. J. Surg. Oncol.46(8), 1539–1542 (2020).
   PubMed Web of Science ®Google Scholar
• Dreyer S , PineseM , JamiesonNet al. 10. Precision oncology in surgery: patient selection biomarkers for operable pancreatic cancer. Eur. J. Surg. Oncol.44(11), 1838 (2018).
   Google Scholar
• Mueller S , EngleitnerT , MareschRet al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature554(7690), 62–68 (2018).
   PubMed Web of Science ®Google Scholar
• Bibikova M , LeJ , BarnesBet al. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics1(1), 177–200 (2009).
   PubMed Web of Science ®Google Scholar
• Shapiro J , Van LanschotJJB , HulshofMet al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol.16(9), 1090–1098 (2015).
   PubMed Web of Science ®Google Scholar
• Al-Batran SE , HomannN , PauligkCet al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, Phase 2/3 trial. Lancet393(10184), 1948–1957 (2019).
   PubMed Web of Science ®Google Scholar
• Shivnani AT , SmallW , StrykerSJet al. Preoperative chemoradiation for rectal cancer: results of multimodality management and analysis of prognostic factors. Am. J. Surg.193(3), 389–394 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrone CR , MarchegianiG , HongTSet al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann. Surg.261(1), 12–17 (2015).
   PubMed Web of Science ®Google Scholar
• Wagner M , AntunesC , PietraszDet al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur. Radiol.27(7), 3104–3116 (2016).
   PubMed Web of Science ®Google Scholar
• Oba A , HoF , BaoQR , Al-MusawiMH , SchulickRD , DelChiaro M. Neoadjuvant treatment in pancreatic cancer. Front. Oncol.10, 245 (2020).
   PubMed Web of Science ®Google Scholar
• Conroy T , DesseigneF , YchouMet al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Eng. J. Med.364(19), 1817–1825 (2011).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD , RamanathanRK , BoradMJet al. Gemcitabine plusnab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J. Clin. Oncol.29(34), 4548–4554 (2011).
   PubMed Web of Science ®Google Scholar
• Rangelova E , WeferA , PerssonSet al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer. Ann. Surg.273(3), 579–586 (2019).
   Web of Science ®Google Scholar
• Tee MC , KrajewskiAC , GroeschlRTet al. Indications and perioperative outcomes for pancreatectomy with arterial resection. J. Am. Coll. Surg.227(2), 255–269 (2018).
   PubMed Web of Science ®Google Scholar
• Peddi PF , LubnerS , McwilliamsRet al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP13(5), 497–501 (2012).
   PubMedGoogle Scholar
• Macedo FI , RyonE , MaithelSKet al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or Gemcitabine/Nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann. Surg.270(3), 400–413 (2019).
   PubMed Web of Science ®Google Scholar
• Hackert T , SachsenmaierM , HinzUet al. Locally advanced pancreatic cancer. Ann. Surg.264(3), 457–463 (2016).
   PubMed Web of Science ®Google Scholar
• Byun Y , HanY , KangJSet al. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J. Hepatobiliary Pancreat. Sci.26(9), 416–425 (2019).
   PubMed Web of Science ®Google Scholar
• Reni M , BalzanoG , ZanonSet al. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. Br. J. Cancer115(3), 290–296 (2016).
   PubMed Web of Science ®Google Scholar
• Reni M , ZanonS , BalzanoGet al. A randomised Phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Eur. J. Cancer102, 95–102 (2018).
   PubMed Web of Science ®Google Scholar
• Philip PA , LacyJ , PortalesFet al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label Phase 2 study. Lancet Gastroenterol. Hepatol.5(3), 285–294 (2020).
   PubMed Web of Science ®Google Scholar
• Ghaneh P , PalmerDH , CicconiSet al. ESPAC-5F: four-arm, prospective, multicenter, international randomized Phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J. Clin. Oncol.38(Suppl. 15), 4505–4505 (2020).
   Web of Science ®Google Scholar
• Versteijne E , SukerM , GroothuisKet al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized Phase III PREOPANC trial. J. Clin. Oncol.38(16), 1763–1773 (2020).
   PubMed Web of Science ®Google Scholar
• Rose JB , RochaFG , AlseidiAet al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann. Surg. Oncol.21(5), 1530–1537 (2014).
   PubMed Web of Science ®Google Scholar
• Janssen QP , BuettnerS , SukerMet al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J. Natl Cancer Inst.111(8), 782–794 (2019).
   PubMedGoogle Scholar
• Suker M , BeumerBR , SadotEet al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol.17(6), 801–810 (2016).
   PubMed Web of Science ®Google Scholar
• Merkow RP , BilimoriaKY , TomlinsonJSet al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann. Surg.260(2), 372–377 (2014).
   PubMed Web of Science ®Google Scholar
• Motoi F , KosugeT , UenoHet al. Randomized Phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J. Clin. Oncol.49(2), 190–194 (2019).
   PubMed Web of Science ®Google Scholar
• Golcher H , BrunnerTB , WitzigmannHet al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer. Strahlenther. Onkol.191(1), 7–16 (2014).
   PubMed Web of Science ®Google Scholar
• O’reilly EM , PerelshteynA , JarnaginWRet al. A single-arm, nonrandomized Phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann. Surg.260(1), 142–148 (2014).
   PubMed Web of Science ®Google Scholar
• Tzeng C-WD , FlemingJB , LeeJEet al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann. Surg. Oncol.19(6), 2045–2053 (2012).
   PubMed Web of Science ®Google Scholar
• Gillen S , SchusterT , BüschenfeldeZum Meyer C , FriessH , KleeffJ. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med.7(4), e1000267 (2010).
   PubMed Web of Science ®Google Scholar
• Satoi S , YamamotoT , YamakiS , SakaguchiT , SekimotoM. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann. Gastroenterol. Surg.4(1), 6–13 (2019).
   PubMed Web of Science ®Google Scholar
• Herbst B , ZhengL. Precision medicine in pancreatic cancer: treating every patient as an exception. Lancet Gastroenterol. Hepatol.4(10), 805–810 (2019).
   PubMed Web of Science ®Google Scholar
• Wang CF . Significance of precision medicine in pancreatic cancer prevention and treatment. Zhonghua Zhong Liu Za Zhi38(3), 161–164 (2016).
   PubMedGoogle Scholar
• Tsai S , ChristiansKK , GeorgeBet al. A Phase II clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma. Ann. Surg.268(4), 610–619 (2018).
   PubMed Web of Science ®Google Scholar
• Chantrill LA , NagrialAM , WatsonCet al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin. Cancer Res.21(9), 2029–2037 (2015).
   PubMed Web of Science ®Google Scholar
• Dreyer SB , JamiesonNB , MortonJP , SansomOJ , BiankinAV , ChangDK. Pancreatic cancer: from genome discovery to PRECISION-Panc. Clin. Oncol.32(1), 5–8 (2020).
   Web of Science ®Google Scholar